



April 30, 1999 / Vol. 48 / No. RR-4

**MMWR**<sup>TM</sup>  
MORBIDITY AND MORTALITY  
WEEKLY REPORT

*Recommendations  
and  
Reports*

***Inside: Continuing Education Examination***

---

## **Prevention and Control of Influenza**

**Recommendations of the Advisory  
Committee on Immunization Practices (ACIP)**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES**  
Centers for Disease Control and Prevention (CDC)  
Atlanta, Georgia 30333



The *MMWR* series of publications is published by the Epidemiology Program Office, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333.

**SUGGESTED CITATION**

Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 1999;48(No. RR-4):[inclusive page numbers].

Centers for Disease Control and Prevention ..... Jeffrey P. Koplan, M.D., M.P.H.  
*Director*

The material in this report was prepared for publication by  
National Center for Infectious Diseases ..... James M. Hughes, M.D.  
*Director*

Division of Viral and Rickettsial Diseases ..... Brian W.J. Mahy, Ph.D., Sc.D.  
*Director*

The production of this report as an *MMWR* serial publication was coordinated in  
Epidemiology Program Office ..... Stephen B. Thacker, M.D., M.Sc.  
*Director*

Office of Scientific and Health Communications ..... John W. Ward, M.D.  
*Director*  
*Editor, MMWR Series*

*Recommendations and Reports* ..... Suzanne M. Hewitt, M.P.A.  
*Managing Editor*

Valerie R. Johnson  
*Project Editor*

Morie M. Higgins  
*Visual Information Specialist*

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

Copies can be purchased from Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402-9325. Telephone: (202) 512-1800.

## Contents

Introduction .....	1
Increases in Vaccination Coverage Levels .....	1
Influenza and Its Burden.....	2
Biology of Influenza .....	2
Clinical Signs and Symptoms of Influenza .....	2
Hospitalizations and Deaths From Influenza .....	2
Options for Controlling Influenza.....	4
Influenza Vaccine.....	4
Antiviral Agents .....	5
Recommendations for the Use of Influenza Vaccine .....	5
Target Groups for Vaccination .....	5
Persons at High Risk for Influenza-Related Complications .....	5
Persons Who Can Transmit Influenza to Those at High Risk .....	6
Other Groups To Consider .....	7
Persons Infected with Human Immunodeficiency Virus.....	7
Breastfeeding Mothers .....	8
Travelers .....	8
General Population .....	8
Persons Who Should Not Be Vaccinated .....	8
Administration of Influenza Vaccine .....	9
Timing .....	9
Dosage .....	9
Route.....	10
Side Effects and Adverse Reactions .....	10
Local Reactions .....	10
Systemic Reactions.....	10
Guillain-Barré Syndrome .....	11
Simultaneous Administration of Other Vaccines, Including Childhood Vaccines.....	12
Strategies for Implementing These Recommendations	
in Health-Care Settings.....	12
Outpatient Facilities Providing Ongoing Care .....	13
Outpatient Facilities Providing Episodic or Acute Care .....	13
Nursing Homes and Other Residential Long-Term Care Facilities.....	13
Acute-Care Hospitals .....	13
Visiting Nurses and Others Providing Home Care to Persons at High Risk.....	13
Other Facilities Providing Services to Persons Aged $\geq 65$ Years.....	13
Other Health-Care Workers .....	13

Evolving Developments Related to Influenza Vaccine .....	14
Potential New Vaccines .....	14
Potential Expansion of Groups Recommended for Vaccination .....	14
Recommendations for the Use of Antiviral Agents for Influenza A .....	15
Indications for Use .....	15
Role of Viral Diagnosis .....	16
Administration of Amantadine and Rimantadine.....	16
Use for Prophylaxis.....	16
Use for Treatment .....	17
Use for the Control of Influenza Outbreaks in Institutions .....	17
Dosage .....	18
Route.....	20
Pharmacokinetics .....	20
Side Effects and Adverse Reactions .....	21
Drug Interactions.....	21
Antiviral Drug-Resistant Strains of Influenza .....	21
Evolving Developments Related to Antiviral Agents for Influenza.....	22
Sources of Information on Influenza and Its Surveillance .....	22
Acknowledgment.....	23
References.....	23
Continuing Education Examination .....	CE-1

## Advisory Committee on Immunization Practices Membership List, March 1999

### CHAIRMAN

John F. Modlin, M.D.  
Professor of Pediatrics and Medicine  
Dartmouth Medical School  
Lebanon, New Hampshire

### EXECUTIVE SECRETARY

Dixie E. Snider, Jr., M.D., M.P.H.  
Associate Director for Science  
Centers for Disease Control  
and Prevention  
Atlanta, Georgia

### MEMBERS

Richard D. Clover, M.D.  
University of Louisville  
School of Medicine  
Louisville, Kentucky

David W. Fleming, M.D.  
Oregon Health Division  
Portland, Oregon

Mary P. Glode, M.D.  
The Children's Hospital  
Denver, Colorado

Marie R. Griffin, M.D., M.P.H.  
Vanderbilt University Medical Center  
Nashville, Tennessee

Fernando A. Guerra, M.D.  
San Antonio Metropolitan Health District  
San Antonio, Texas

Charles M. Helms, M.D., Ph.D.  
University of Iowa Hospital and Clinics  
Iowa City, Iowa

David R. Johnson, M.D., M.P.H.  
Michigan Department of  
Community Health  
Lansing, Michigan

Chinh T. Le, M.D.  
Kaiser Permanente Medical Center  
Santa Rosa, California

Paul A. Offit, M.D.  
The Children's Hospital of Philadelphia  
Philadelphia, Pennsylvania

Jessie L. Sherrod, M.D.  
King Drew Medical Center  
Los Angeles, California

Bonnie M. Word, M.D.  
Monmouth Junction, New Jersey

### EX OFFICIO MEMBERS

Robert F. Breiman, M.D.  
Centers for Disease Control  
and Prevention  
Atlanta, Georgia

William Egan, Ph.D.  
Food and Drug Administration  
Rockville, Maryland

Geoffrey S. Evans, M.D.  
Health Resources and  
Services Administration  
Rockville, Maryland

T. Randolph Graydon  
Center for Medicaid and  
State Operations  
Baltimore, Maryland

## Advisory Committee on Immunization Practices Membership List, March 1999 — Continued

Regina Rabinovich, M.D.  
National Institutes of Health  
Bethesda, Maryland

Kristin Lee Nichol, M.D., M.P.H.  
VA Medical Center  
Minneapolis, Minnesota

David H. Trump, M.D., M.P.H.  
Office of the Assistant Secretary  
of Defense (Health Affairs)  
Falls Church, Virginia

### LIAISON REPRESENTATIVES

American Academy of Family Physicians  
Richard Zimmerman, M.D.  
Pittsburgh, Pennsylvania

American Academy of Pediatrics  
Larry Pickering, M.D.  
Norfolk, Virginia  
Jon Abramson, M.D.  
Winston-Salem, North Carolina

American Association of Health Plans  
(*Vacant*)

American College of Obstetricians  
and Gynecologists  
Stanley A. Gall, M.D.  
Louisville, Kentucky

American College of Physicians  
Pierce Gardner, M.D.  
Stony Brook, New York

American Hospital Association  
William Schaffner, M.D.  
Nashville, Tennessee

American Medical Association  
H. David Wilson, M.D.  
Grand Forks, North Dakota

Association of Teachers of  
Preventive Medicine  
W. Paul McKinney, M.D.  
Louisville, Kentucky

Biotechnology Industry Organization  
Yvonne E. McHugh, Ph.D.  
Emeryville, California

Canadian National Advisory  
Committee on Immunization  
Victor Marchessault, M.D.  
Cumberland, Ontario, Canada

Hospital Infection Control Practices  
Advisory Committee  
Jane D. Siegel, M.D.  
Dallas, Texas

Infectious Diseases Society of America  
Samuel L. Katz, M.D.  
Durham, North Carolina

National Immunization Council and  
Child Health Program, Mexico  
Jose Ignacio Santos, M.D.  
Mexico City, Mexico

National Medical Association  
Rudolph E. Jackson, M.D.  
Atlanta, Georgia

National Vaccine Advisory Committee  
Georges Peter, M.D.  
Providence, Rhode Island

Pharmaceutical Research and  
Manufacturers of America  
(*Vacant*)

## Members of the Influenza Working Group Advisory Committee on Immunization Practices (ACIP)

Fernando A. Guerra, M.D., Chairman  
Robert F. Breiman, M.D.  
Richard D. Clover, M.D.  
T. Randolph Graydon  
Marie R. Griffin, M.D., M.P.H.  
Charles M. Helms, M.D., Ph.D.  
John F. Modlin, M.D.  
Kristin Lee Nichol, M.D., M.P.H.  
*ACIP*

Jon Abramson, M.D.  
*American Academy of Pediatrics*

Matthew L. Cartter, M.D., M.P.H.  
*Connecticut Department of Public Health*

Pierce Gardner, M.D.  
*American College of Physicians*

Peter Paradiso, M.D.  
*Wyeth-Lederle Vaccines and Pediatrics*

Peter A. Patriarca, M.D.  
*Food and Drug Administration*

Fred Reuben, M.D.  
*Pharmaceutical Research and Manufacturers of America*

William Schaffner, M.D.  
*American Hospital Association*

Richard Zimmerman, M.D.  
*American Academy of Family Physicians*

Robert T. Chen, M.D.  
Nancy J. Cox, Ph.D.  
Keiji Fukuda, M.D., M.P.H.  
*Centers for Disease Control and Prevention*

**The following CDC staff members prepared this report:**

Keiji Fukuda, M.D., M.P.H.

Carolyn B. Bridges, M.D.

T. Lynnette Brammer, M.P.H.

Hector S. Izurieta, M.D., M.P.H.

Nancy J. Cox, Ph.D.

*Division of Viral and Rickettsial Diseases  
National Center for Infectious Diseases*



# Prevention and Control of Influenza:

## Recommendations of the Advisory Committee on Immunization Practices (ACIP)

### Summary

*This report updates 1998 recommendations by the Advisory Committee on Immunization Practices (ACIP) on the use of influenza vaccine and antiviral agents (MMWR 1998;47[No. RR-6]:1–26). The principal changes include a) information on the influenza virus strains included in the 1999–2000 trivalent vaccine; b) discussion of the potential expanded use of influenza vaccine; c) new background information on live-attenuated influenza vaccines (LAIVs), neuraminidase-inhibitor drugs, and rapid diagnostic tests; d) new information on the epidemiology of influenza among travelers; and e) the addition of referenced citations. This report and other information on influenza can be accessed at the website for the Influenza Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, CDC at <<http://www.cdc.gov/ncidod/diseases/flu/fluvirus.htm>>.*

## INTRODUCTION

Epidemics of influenza occur during the winter months nearly every year and are responsible for an average of approximately 20,000 deaths per year in the United States (1,2). Influenza viruses also can cause global epidemics of disease, known as pandemics, during which rates of morbidity and mortality from influenza-related complications can increase dramatically. Influenza viruses cause disease in all age groups (3,4). Rates of infection are highest among children, but rates of serious morbidity and mortality are highest among persons aged  $\geq 65$  years and persons of any age who have medical conditions that place them at high risk for complications from influenza (3,5–7).

Influenza vaccine is the primary method for preventing influenza and its more severe complications. In this report from the Advisory Committee on Immunization Practices (ACIP), the primary target group for the influenza vaccination recommendations includes persons who are at high risk for serious complications from influenza, including approximately 34 million persons aged  $\geq 65$  years and approximately 32 million persons aged  $< 65$  years who have chronic underlying medical conditions (National Immunization Program, CDC, unpublished data, 1999).

## Increases in Vaccination Coverage Levels

Among persons aged  $\geq 65$  years, influenza vaccination levels have increased from 33% in 1989 (8) to 65.5% in 1997 (9). The 1997 vaccination coverage level surpassed the *Healthy People 2000* goal of 60% (10). Although influenza vaccination coverage increased in black, Hispanic, and white populations, coverage levels among blacks and Hispanics continue to lag behind levels among whites (9). Possible reasons for

the increase in influenza vaccination levels among persons aged  $\geq 65$  years include greater acceptance of preventive medical services by practitioners, increased delivery and administration of vaccine by health-care providers and sources other than physicians, and the initiation of Medicare reimbursement for influenza vaccination in 1993 (11).

The cost-effectiveness and cost savings of influenza vaccination is predicated on a good antigenic match between the vaccine and circulating virus strains. One recent study reported a cost savings when healthy adults were vaccinated (12). Other studies suggest that the use of trivalent inactivated influenza vaccine or live attenuated influenza vaccine decreases the incidence of otitis media and the use of antibiotics among children (13–15). Despite these reported benefits, <30% of persons who are aged <65 years and at high risk for influenza-related complications are vaccinated each year (16,17). Increasing vaccination coverage among these high-risk groups now is the highest priority for expanding influenza vaccine use.

## **Influenza and Its Burden**

### ***Biology of Influenza***

Influenza A and B are the two types of influenza viruses that cause epidemic human disease (18). Influenza A viruses are further classified into subtypes on the basis of two surface antigens: hemagglutinin (H) and neuraminidase (N). Although both influenza A and B viruses undergo continual antigenic change (i.e., antigenic drift), influenza B viruses undergo antigenic drift less rapidly and are not divided into subtypes. Since 1977, influenza A (H1N1) viruses, influenza A (H3N2) viruses, and influenza B viruses have been in global circulation.

A person's immunity to the surface antigens, especially hemagglutinin, reduces the likelihood of infection and the severity of disease if infection occurs (19). However, antibody against one influenza virus type or subtype confers little or no protection against another virus type or subtype. Furthermore, antibody to one strain of influenza virus might not protect against a distantly related strain of the same subtype (20). The constant development of antigenic variants through antigenic drift is the virologic basis for seasonal epidemics and the reason for the incorporation of one or more new virus strains in each year's influenza vaccine.

### ***Clinical Signs and Symptoms of Influenza***

Uncomplicated influenza illness is characterized by the abrupt onset of constitutional and respiratory signs and symptoms (e.g., fever, myalgia, headache, severe malaise, sore throat, rhinitis, and nonproductive cough) (21). Illness typically resolves after several days for most persons, although cough and malaise can persist for 2 or more weeks. In some persons, influenza can exacerbate underlying medical conditions (e.g., pulmonary or cardiac disease) or lead to secondary bacterial pneumonia or primary influenza viral pneumonia (22).

### ***Hospitalizations and Deaths From Influenza***

The risks for complications, hospitalization, and death from influenza are higher among persons aged  $\geq 65$  years and persons of any age with some underlying health

conditions than among healthy children and adults (1,22–25). Estimated rates of influenza-associated hospitalizations have varied substantially in studies of different influenza epidemics occurring from 1972 through 1981:

- Among children aged 0–4 years, rates have ranged from approximately 500 per 100,000 population for those with high-risk conditions to 100 per 100,000 population for those without high-risk conditions (26).
- Among children aged 5–14 years, rates have ranged from approximately 200 per 100,000 population for those with high-risk conditions to 20 per 100,000 population for those without high-risk conditions (26).
- Among persons aged 15–44 years, rates have ranged from approximately 40 to 60 per 100,000 population for those with high-risk conditions and from approximately 20 to 30 per 100,000 population for those without high-risk conditions (5,6).
- Among persons aged 45–64 years, rates have ranged from approximately 80 to 400 per 100,000 population for those with high-risk medical conditions and from approximately 20 to 40 per 100,000 population for those without high-risk conditions (6,26).
- Among persons aged  $\geq 65$  years, rates have ranged from approximately 200 to  $>1,000$  per 100,000 population (6,26,27).

During influenza epidemics from 1969–1970 through 1993–1994, the estimated number of influenza-associated hospitalizations in the United States has ranged from approximately 20,000 to  $>300,000$  per epidemic. A review of national data indicate an average of approximately 110,000 hospitalizations per year are related to influenza. Since the 1968 influenza A (H3N2) virus pandemic, the greatest numbers of influenza-associated hospitalizations have occurred during epidemics caused by type A(H3N2) viruses, with an estimated average of 148,000 influenza-associated hospitalizations each year (Influenza Branch, Division of Viral and Rickettsial Diseases [DVRD], National Center for Infectious Diseases [NCID], CDC, unpublished data, 1999).

During influenza epidemics, deaths can increase from influenza and pneumonia as well as from exacerbations of cardiopulmonary conditions and other chronic diseases. In studies of influenza epidemics occurring from 1972–1973 through 1994–1995, excess deaths (i.e., the number of influenza-related deaths above a projected baseline of expected deaths) occurred during 19 of 23 influenza epidemics (28) (Influenza Branch, DVRD, NCID, CDC, unpublished data, 1998). During those 19 influenza seasons, estimated rates of influenza-associated death ranged from approximately 25 to  $>150$  deaths per 100,000 persons aged  $\geq 65$  years (29). These older adults account for approximately 90% of the deaths attributed to pneumonia and influenza (29). From 1972–1973 through 1994–1995, an estimated  $>20,000$  influenza-associated deaths occurred during each of 11 different U.S. epidemics, and  $>40,000$  influenza-associated deaths occurred during each of six of these 11 epidemics (28) (Influenza Branch, DVRD, NCID, CDC, unpublished data, 1998). In the United States, pneumonia and influenza deaths might be increasing in part because the number of elderly persons is increasing (30).

## Options for Controlling Influenza

In the United States, the main option for reducing the impact of influenza is immunoprophylaxis with inactivated (i.e., killed-virus) vaccine (see Recommendations for the Use of Influenza Vaccine). In addition, the use of influenza-specific antiviral drugs (amantadine or rimantadine) for chemoprophylaxis or therapy of influenza A infection is an important adjunct to vaccine (see Recommendations for the Use of Antiviral Agents for Influenza A).

### *Influenza Vaccine*

Vaccinating persons at high risk for complications before the influenza season each year is the most effective means of reducing the impact of influenza. Vaccination coverage can be increased by administering vaccine to persons during hospitalizations or routine health-care visits before the influenza season, making special visits to physicians' offices or clinics unnecessary. When vaccine and epidemic strains of virus are well matched, achieving high vaccination rates among persons living in closed settings (e.g., nursing homes and other chronic-care facilities) and among the staff can reduce the risk for outbreaks by inducing herd immunity (31).

#### *Effectiveness of Inactivated Influenza Vaccine*

Influenza vaccine now contains three virus strains (usually two type A and one type B), representing the influenza viruses likely to circulate in the United States in the upcoming winter. The vaccine is made from highly purified, egg-grown viruses that have been made noninfectious (inactivated) (32). Whole-virus, subvirion, and purified-surface-antigen preparations are available.

Most vaccinated children and young adults develop high postvaccination hemagglutination-inhibition antibody titers (33,34). These antibody titers are protective against illness caused by strains similar to those in the vaccine (34-36). Elderly persons and persons with certain chronic diseases might develop lower postvaccination antibody titers than healthy young adults and thus can remain susceptible to influenza-related upper respiratory tract infection (37-39). However, among such persons, the vaccine can be effective in preventing secondary complications and reducing the risk for hospitalization and death (31,40,41).

The effectiveness of influenza vaccine depends primarily on the age and immunocompetence of the vaccine recipient and the degree of similarity between the virus strains in the vaccine and those in circulation. When the antigenic match between vaccine and circulating viruses is close, influenza vaccine prevents illness in approximately 70%-90% of healthy persons younger than age 65 years (42). Among elderly persons living outside nursing homes or similar chronic-care facilities, influenza vaccine is 30%-70% effective in preventing hospitalization for pneumonia and influenza (41,43). Among elderly persons residing in nursing homes, influenza vaccine is most effective in preventing severe illness, secondary complications, and deaths. In this population, the vaccine can be 50%-60% effective in preventing hospitalization or pneumonia and 80% effective in preventing death, even though the effectiveness in preventing influenza illness often ranges from 30% to 40% (44,45).

### ***Influenza Strains Contained in the 1999–2000 Vaccine***

The trivalent influenza vaccine prepared for the 1999–2000 season will include A/Beijing/262/95-like (H1N1), A/Sydney/5/97-like (H3N2), and B/Beijing/184/93-like hemagglutinin antigens. For the B/Beijing/184/93-like antigen, U.S. manufacturers will use the antigenically equivalent B/Yamanashi/166/98 virus because of its growth properties and because it is representative of currently circulating B viruses.

### ***Antiviral Agents***

In the United States, two antiviral agents are licensed for use in preventing and treating influenza A: amantadine hydrochloride and rimantadine hydrochloride. These antiviral drugs are an important adjunct to influenza vaccine. As a prophylaxis, these agents are appropriate for persons who are at high risk of influenza complications and who are vaccinated after influenza activity has begun; persons who provide care to those at high risk; persons with immune deficiency; and some persons who are at high risk but who cannot be vaccinated. Moreover, these agents can prevent influenza illness while allowing subclinical infection, thus allowing some persons to develop protective immune responses to circulating influenza viruses. As a treatment, both amantadine and rimantadine can shorten the duration of influenza A illness among healthy adults and children.

## **RECOMMENDATIONS FOR THE USE OF INFLUENZA VACCINE**

Influenza vaccine is strongly recommended for any person aged  $\geq 6$  months who — because of age or underlying medical condition — is at increased risk for complications of influenza. In addition, health-care workers and others (including household members) in close contact with persons in high-risk groups should be vaccinated to decrease the risk of transmitting infection to persons at high risk. Influenza vaccine also can be administered to any person who wishes to reduce the chance of becoming infected with influenza (the vaccine can be administered to children as young as 6 months).

### **Target Groups for Vaccination**

#### ***Persons at High Risk for Influenza-Related Complications***

Vaccination is recommended for the following groups of persons who are at increased risk for complications from influenza:

- persons aged  $\geq 65$  years;
- residents of nursing homes and other chronic-care facilities that house persons of any age who have chronic medical conditions;
- adults and children who have chronic disorders of the pulmonary or cardiovascular systems, including asthma;

- adults and children who have required regular medical follow-up or hospitalization during the preceding year because of chronic metabolic diseases (including diabetes mellitus), renal dysfunction, hemoglobinopathies, or immunosuppression (including immunosuppression caused by medications);
- children and teenagers (aged 6 months to 18 years) who are receiving long-term aspirin therapy and therefore might be at risk for developing Reye syndrome after influenza; and
- women who will be in the second or third trimester of pregnancy during the influenza season.

Influenza-associated excess mortality among pregnant women was documented during the pandemics of 1918–1919 and 1957–1958 (46–49). Case reports and limited studies also suggest that pregnancy can increase the risk for serious medical complications of influenza as a result of increases in heart rate, stroke volume, and oxygen consumption; decreases in lung capacity; and changes in immunologic function (50–53). A study of the impact of influenza during 17 interpandemic influenza seasons demonstrated that the relative risk for hospitalization for selected cardiorespiratory conditions among pregnant women enrolled in Medicaid increased from 1.4 during weeks 14–20 of gestation to 4.7 during weeks 37–42 in comparison with women who were 1–6 months postpartum (54). Women in their third trimester of pregnancy were hospitalized at a rate (250 per 100,000 pregnant women) comparable to that of non-pregnant women with high-risk medical conditions. Using data from this study, researchers estimated that an average of 1–2 hospitalizations could be prevented for every 1,000 pregnant women vaccinated.

Women who will be beyond the first trimester of pregnancy ( $\geq 14$  weeks' gestation) during the influenza season should be vaccinated. Pregnant women who have medical conditions that increase their risk for complications from influenza should be vaccinated before the influenza season — regardless of the stage of pregnancy.

Because currently available influenza vaccine is an inactivated vaccine, many experts consider influenza vaccination safe during any stage of pregnancy. A study of influenza vaccination of more than 2,000 pregnant women demonstrated no adverse fetal effects associated with influenza vaccine (55). However, more data are needed to confirm the safety of vaccination during pregnancy. Some experts prefer to administer influenza vaccination during the second trimester to avoid a coincidental association with spontaneous abortion, which is common in the first trimester, and because exposures to vaccines have traditionally been avoided during the first trimester.

### ***Persons Who Can Transmit Influenza to Those at High Risk***

Persons who are clinically or subclinically infected can transmit influenza virus to persons at high risk for complications from influenza. Efforts to protect members of high-risk groups against influenza might be improved by reducing the likelihood of influenza exposure from their care givers. Therefore, the following groups should be vaccinated:

- physicians, nurses, and other personnel in both hospital and outpatient-care settings;
- employees of nursing homes and chronic-care facilities who have contact with patients or residents;
- employees of assisted living and other residences for persons in high-risk groups;
- persons who provide home care to persons in high-risk groups; and
- household members (including children) of persons in high-risk groups.

## Other Groups To Consider

### ***Persons Infected with Human Immunodeficiency Virus***

Limited information exists regarding the frequency and severity of influenza illness or the benefits of influenza vaccination among persons with human immunodeficiency virus (HIV) infection (56). However, a recent retrospective study of young and middle-aged women enrolled in Tennessee's Medicaid program found that the attributable risk for cardiopulmonary hospitalizations among women with HIV infection was higher during influenza seasons than in the peri-influenza periods. The risk of hospitalization for HIV-infected women was higher than the risk for women with other well-recognized high-risk conditions for influenza complications, including chronic heart and lung diseases (57). Other reports suggest that influenza symptoms might be prolonged and the risk for complications from influenza increased for some HIV-infected persons (58,59).

Influenza vaccine has produced substantial antibody titers against influenza in vaccinated HIV-infected persons who have minimal acquired immunodeficiency syndrome-related symptoms and high CD4+ T-lymphocyte cell counts (60–63). However, in patients who have advanced HIV disease and low CD4+ T-lymphocyte cell counts, influenza vaccine might not induce protective antibody titers (62,63); a second dose of vaccine does not improve the immune response in these persons (63,64).

One study found that HIV RNA levels increased transiently in one HIV-infected patient after influenza infection (65). Some studies have demonstrated a transient (i.e., 2- to 4-week) increase in replication of HIV-1 in the plasma or peripheral blood mononuclear cells of HIV-infected persons after vaccine administration (62,66). Other studies using similar laboratory techniques have not documented a substantial increase in the replication of HIV (67–69). Deterioration of CD4+ T-lymphocyte cell counts and progression of HIV disease have not been demonstrated among HIV-infected persons who receive vaccine. The effect of antiretroviral therapy on potential increases in HIV RNA levels following either natural influenza infection or influenza vaccination is unknown (56). Because influenza can result in serious illness and complications and because influenza vaccination can result in the production of protective antibody titers, vaccination will benefit many HIV-infected patients, including HIV-infected pregnant women.

### ***Breastfeeding Mothers***

Influenza vaccine does not affect the safety of mothers who are breastfeeding or their infants. Breastfeeding does not adversely affect immune response and is not a contraindication for vaccination.

### ***Travelers***

The risk of exposure to influenza during travel depends on the time of year and destination. In the tropics, influenza can occur throughout the year, whereas most influenza activity occurs from April through September in the temperate regions of the Southern Hemisphere. In temperate climate zones of the Northern and Southern Hemispheres, travelers also can be exposed to influenza during the summer, especially when traveling as part of large organized tourist groups containing persons from areas of the world where influenza viruses are circulating.

Persons at high risk for complications of influenza should consider receiving influenza vaccine before travel if they were not vaccinated with influenza vaccine during the preceding fall or winter and they plan to a) travel to the tropics; b) travel with large organized tourist groups at any time of year; or c) travel to the Southern Hemisphere from April through September. Persons at high risk who received the previous season's vaccine before travel should be revaccinated with the current vaccine in the following fall or winter.

Because influenza vaccine might not be available during the summer in North America, persons aged  $\geq 65$  years and others at high risk might wish to consult with their physicians before embarking on travel during the summer to discuss the symptoms and risks of influenza and advisability of carrying antiviral medications for either prophylaxis or treatment for influenza.

### ***General Population***

Physicians should administer influenza vaccine to any person who wishes to reduce the likelihood of becoming ill with influenza (the vaccine can be administered to children as young as 6 months). Persons who provide essential community services should be considered for vaccination to minimize disruption of essential activities during influenza outbreaks. Students or other persons in institutional settings (e.g., those who reside in dormitories) should be encouraged to receive vaccine to minimize the disruption of routine activities during epidemics.

### **Persons Who Should Not Be Vaccinated**

Inactivated influenza vaccine should not be administered to persons known to have anaphylactic hypersensitivity to eggs or to other components of the influenza vaccine without first consulting a physician (see Side Effects and Adverse Reactions). Use of an antiviral agent (amantadine or rimantadine) is an option for preventing influenza A among such persons. However, persons who have a history of anaphylactic hypersensitivity to vaccine components but who are also at high risk for complications of influenza can benefit from vaccine after appropriate allergy evaluation and desensitization. Information about vaccine components can be found in package inserts from each manufacturer.



Persons with acute febrile illness usually should not be vaccinated until their symptoms have abated. However, minor illnesses with or without fever do not contraindicate the use of influenza vaccine, particularly among children with mild upper respiratory tract infection or allergic rhinitis.

## Administration of Influenza Vaccine

### Timing

Beginning each September, influenza vaccine should be offered to persons at high risk when they are seen by health-care providers for routine care or as a result of hospitalization. For organized vaccination campaigns, the optimal time to vaccinate persons in high-risk groups is usually from October through mid-November, because influenza activity in the United States generally peaks between late December and early March. Administering vaccine too far in advance of the influenza season should be avoided in facilities such as nursing homes, because antibody levels can begin to decline within a few months of vaccination (70,71). If regional influenza activity is expected to begin earlier than December, vaccination programs can be undertaken as soon as current vaccine is available. Vaccine should be offered to unvaccinated persons even after influenza virus activity is documented in a community.

### Dosage

Dosage recommendations vary according to age group (Table 1). Among previously unvaccinated children aged <9 years, two doses administered at least 1 month apart are recommended for satisfactory antibody responses. If possible, the second dose should be administered before December. Among adults, studies have indicated little or no improvement in antibody response when a second dose is administered during the same season (72–75).

**TABLE 1. Influenza vaccine\* dosage, by age group — United States, 1999–2000 season**

Age group	Product†	Dose	No. of doses	Route§
6–35 mos	Split virus only	0.25 mL	1 or 2¶	IM**
3– 8 yrs	Split virus only	0.50 mL	1 or 2¶	IM
9–12 yrs	Split virus only	0.50 mL	1	IM
>12 yrs	Whole or split virus	0.50 mL	1	IM

\* Contains 15 µg each of A/Beijing/262/95-like (H1N1), A/Sydney/5/97-like (H3N2), and B/Beijing/184/93-like hemagglutinin antigens in each 0.5 mL. For the B/Beijing/184/93-like antigen, U.S. manufacturers will use the antigenically equivalent B/Yamanashi/166/98 strain because of its growth properties. Manufacturers include Connaught Laboratories, Inc. (Fluzone® whole or split); Medeva Pharma Ltd. (Fluvirin™ purified surface antigen vaccine); Parkedale Pharmaceuticals, Inc. (Fluogen® split); and Wyeth-Ayerst Laboratories (Flushield™ split). For further product information call Connaught, (800) 822-2463; Medeva, (800) 234-5535; Parkedale, (888) 358-6436; or Wyeth-Ayerst, (800) 358-7443.

† Because of their decreased potential for causing febrile reactions, only split-virus vaccines should be used for children. They may be labeled as “split,” “subvirion,” or “purified-surface-antigen” vaccine. Immunogenicity and side effects of split- and whole-virus vaccines are similar among adults when vaccines are administered at the recommended dosage.

§ For adults and older children, the recommended site of vaccination is the deltoid muscle. The preferred site for infants and young children is the anterolateral aspect of the thigh.

¶ Two doses administered at least 1 month apart are recommended for children <9 years of age who are receiving influenza vaccine for the first time.

\*\* Intramuscular.

Even when the current influenza vaccine contains one or more of the antigens administered in previous years, annual vaccination with the current vaccine is necessary because immunity declines during the year following vaccination (70,71). Vaccine prepared for a previous influenza season should not be administered to provide protection for the current season.

### **Route**

The intramuscular route is recommended for influenza vaccine. Adults and older children should be vaccinated in the deltoid muscle; a needle length  $\geq 1$  inch can be considered for these age groups. Infants and young children should be vaccinated in the anterolateral aspect of the thigh (76).

## **Side Effects and Adverse Reactions**

When educating patients about potential side effects, clinicians should emphasize that a) inactivated influenza vaccine contains noninfectious killed viruses and cannot cause influenza; and b) respiratory disease after vaccination is coincidental and unrelated to influenza vaccination.

### **Local Reactions**

In placebo-controlled blinded studies, the most frequent side effect of vaccination is soreness at the vaccination site (affecting 10%–64% of patients) that lasts up to 2 days (77–79). These local reactions generally are mild and rarely interfere with the person's ability to conduct usual daily activities.

### **Systemic Reactions**

Fever, malaise, myalgia, and other systemic symptoms can occur following vaccination and most often affect persons who have had no exposure to the influenza virus antigens in the vaccine (e.g., young children) (80,81). These reactions begin 6–12 hours after vaccination and can persist for 1–2 days. Recent placebo-controlled trials suggest that among elderly persons and healthy young adults, split-virus influenza vaccine is not associated with higher rates of systemic symptoms (e.g., fever, malaise, myalgia, and headache) when compared with placebo injections (77–79).

Immediate — presumably allergic — reactions (e.g., hives, angioedema, allergic asthma, and systemic anaphylaxis) rarely occur after influenza vaccination (82). These reactions probably result from hypersensitivity to some vaccine component; most reactions likely are caused by residual egg protein. Although current influenza vaccines contain only a small quantity of egg protein, this protein can induce immediate hypersensitivity reactions among persons who have severe egg allergy. Persons who have developed hives, have had swelling of the lips or tongue, or have experienced acute respiratory distress or collapse after eating eggs should consult a physician for appropriate evaluation to help determine if vaccine should be administered. Persons who have documented immunoglobulin E (IgE)-mediated hypersensitivity to eggs — including those who have had occupational asthma or other allergic responses to egg protein — might also be at increased risk for allergic reactions to influenza vaccine, and consultation with a physician should be considered.

Protocols have been published for safely administering influenza vaccine to persons with egg allergies (83,84).

Hypersensitivity reactions to any vaccine component can occur. Although exposure to vaccines containing thimerosal can lead to induction of hypersensitivity, most patients do not develop reactions to thimerosal when administered as a component of vaccines — even when patch or intradermal tests for thimerosal indicate hypersensitivity (85,86). When reported, hypersensitivity to thimerosal usually has consisted of local, delayed-type hypersensitivity reactions (85).

### **Guillain-Barré Syndrome**

The 1976 swine influenza vaccine was associated with an increased frequency of Guillain-Barré syndrome (GBS) (87,88). Among persons who received the swine influenza vaccine in 1976, the rate of GBS that exceeded the background rate was slightly less than 10 cases per million persons vaccinated. Evidence for a causal relationship of GBS with subsequent vaccines prepared from other virus strains is less clear. Obtaining strong epidemiologic evidence for a possible small increase in risk is difficult for a rare condition such as GBS, which has an annual incidence of only 10–20 cases per million adults (89), and stretches the limits of epidemiologic investigation. More definitive data probably will require the use of other methodologies such as laboratory studies of the pathophysiology of GBS.

During three of four influenza seasons studied from 1977 through 1991, the overall relative risk estimates for GBS after influenza vaccination were slightly elevated but were not statistically significant in any of these studies (90–92). However, in a study of the 1992–1993 and 1993–1994 seasons, the overall relative risk for GBS was 1.7 (95% confidence interval = 1.0–2.8;  $p = 0.04$ ) during the 6 weeks following vaccination, representing an excess of slightly more than one additional case of GBS per million persons vaccinated; the combined number of GBS cases peaked 2 weeks after vaccination (93). Thus, investigations to date suggest no large increase in GBS associated with influenza vaccines (other than the swine influenza vaccine in 1976) and that if influenza vaccine does pose a risk, it is probably quite small — slightly more than one additional case per million persons vaccinated. Cases of GBS following influenza infection have been reported, but no epidemiologic studies have documented such an association (94,95). Good evidence exists that several infectious illnesses, most notably *Campylobacter jejuni* as well as upper respiratory tract infections in general, are associated with GBS (89,96–98).

Even if GBS were a true side effect of vaccination in the years after 1976, the estimated risk for GBS of slightly more than one additional case per million persons vaccinated is substantially less than the risk for severe influenza, which could be prevented by vaccination in all age groups, especially persons aged  $\geq 65$  years and those who have medical indications for influenza vaccination. During different epidemics occurring from 1972 through 1981, estimated rates of influenza-associated hospitalization have ranged from approximately 200 to 300 hospitalizations per million population for previously healthy persons aged 5–44 years and from 2,000 to >10,000 hospitalizations per million population for persons aged  $\geq 65$  years (5,6,26,27). During epidemics from 1972–1973 through 1994–1995, estimated rates of influenza-associated death have ranged from approximately 300 to >1,500 per million persons aged  $\geq 65$  years, who account for more than 90% of all influenza-associated deaths (see

---

## Continuing Education Activity Sponsored by CDC

### Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

#### OBJECTIVE

This *MMWR* provides recommendations regarding the prevention and control of influenza. These recommendations were developed by CDC staff members and the Influenza Working Group of the ACIP. This report is intended to guide clinical practice and policy development related to administration of the influenza vaccine and antiviral agents. Upon completion of this educational activity, the reader should be able to describe the disease burden of influenza in the United States; describe the characteristics of the currently licensed influenza vaccine; identify the primary target groups for annual influenza vaccination; and recognize the most common adverse reactions following administration of influenza vaccine.

#### ACCREDITATION

**Continuing Medical Education (CME) Credit:** This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education (ACCME) through CDC. CDC is accredited by the ACCME to provide continuing medical education for physicians. CDC awards 1.0 hour of category 1 credit toward the AMA Physician's Recognition Award for this activity. Each physician should claim only those hours he/she actually spent in the educational activity.

**Continuing Education Unit (CEU) Credit:** CDC awards 0.1 hour of CEUs. This activity has been structured following the International Association for Continuing Education and Training (IACET) Criteria and Guidelines and therefore is awarding CEUs. The CEU is a nationally recognized unit designed to provide a record of an individual's continuing education accomplishments.

**Continuing Nursing Education (CNE) Credit:** This activity for 1.2 contact hours is provided by CDC, which is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's (ANCC) Commission on Accreditation.

#### EXPIRATION — April 30, 2000

The response form must be completed and returned electronically, by fax, or by mail, **postmarked no later than 1 year from the publication date of this report**, for eligibility to receive continuing education credit.

#### INSTRUCTIONS

1. Read this *MMWR* (Vol. 48, RR-4), which contains the correct answers to the questions beginning on the next page.
2. Complete all registration information on the response form, including your name, mailing address, phone number, and e-mail address, if available.
3. Indicate whether you are registering for Continuing Medical Education (CME) credit, Continuing Education Unit (CEU) credit, or Continuing Nursing Education (CNE) credit.
4. Select your answers to the questions, and mark the corresponding letters on the response form. To receive continuing education credit, you must answer *all* of the questions. Questions with more than one answer will instruct you to "indicate all that are true."
5. Sign and date the response form.
6. Return the response form, or a photocopy of the form, no later than **April 30, 2000**, to CDC by one of the following methods:

Internet: <<http://www2.cdc.gov/cep/>>  
Fax: 404-639-4198

Mail: MMWR CE Credit  
Office of Scientific and Health Communications  
Epidemiology Program Office — MS C08  
Centers for Disease Control and Prevention  
1600 Clifton Road, N.E.  
Atlanta, GA 30333

If you answer all of the questions, you will receive an award letter for 1.0 hour of CME credit, 0.1 hour of CEU credit, or 1.2 hours of CNE credit within 90 days. No fees are charged for participating in this continuing education activity.

U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES



**Prevention and Control of Influenza:  
Recommendations of the Advisory Committee on Immunization Practices (ACIP)**

To receive continuing education credit, please answer all of the following questions.

- 1. Which of the following statements is NOT true concerning the burden of influenza in the United States?**
  - A. Young children are at higher risk for complications of influenza than any other age group.
  - B. Influenza infection can lead to secondary bacterial pneumonia.
  - C. The greatest number of influenza-related hospitalizations occur during epidemics of influenza A (H3N2).
  - D. Recent epidemics have led to more than 40,000 influenza-associated deaths.
  - E. Pneumonia and influenza deaths may be increasing in the United States.
  
- 2. What is the main option for reducing the impact of influenza in the United States?**
  - A. Antibiotics
  - B. Antiviral agents
  - C. Influenza vaccine
  - D. Vitamin supplements
  - E. Smoking cessation programs
  
- 3. Which of the following best describes the currently licensed influenza vaccine?**
  - A. Live attenuated virus
  - B. Inactivated virus
  - C. ReassortantToxoid
  - D. Cloned DNA

- 4. Which of the following is NOT true concerning influenza vaccine?**
- A. Influenza vaccine viruses are grown in eggs.
  - B. Influenza vaccine effectiveness depends on the antigenic similarity between strains of virus in the vaccine and those in circulation.
  - C. Influenza vaccine has been shown to be 70%–90% effective in preventing influenza among healthy persons <65 years of age.
  - D. Influenza vaccine contains two strains of influenza virus.
  - E. Among elderly persons influenza vaccine is more effective in reducing complications of influenza than in preventing influenza illness.
- 5. Which of the following are among the primary target groups for annual influenza vaccination?**
- A. Persons aged 65 years and older.
  - B. Persons with cardiovascular disease.
  - C. Children with asthma.
  - D. Women who will be in the second or third trimester of pregnancy during influenza season.
  - E. All the above are among the primary target groups for annual influenza vaccination
- 6. What is the recommended route of administration of influenza vaccine?**
- A. Intradermal injection
  - B. Subcutaneous injection
  - C. Intramuscular injection
  - D. Intranasal aerosol
  - E. All the above routes of administration are recommended for influenza vaccine.

- 7. Which of the following conditions is a contraindication for the use of influenza vaccine?**
- A. Recent administration of antibody-containing blood product (e.g., whole blood or immune globulin).
  - B. Infection with human immunodeficiency virus (HIV).
  - C. Current administration of antibiotics.
  - D. Severe allergy to a component of the vaccine.
  - E. All of the above are contraindications for the use of influenza vaccine.
- 8. What is the most common adverse reaction following influenza vaccination?**
- A. Soreness at the injection site
  - B. Fever
  - C. An illness identical to influenza
  - D. Allergic reactions, such as angioedema
  - E. Guillain-Barré syndrome
- 9. Which of the following is true concerning currently available antiviral agents for influenza?**
- A. Influenza antiviral agents are equally effective against influenza A and B viruses.
  - B. Influenza antiviral agents are approved for prophylaxis only.
  - C. Influenza antiviral agents can reduce the severity and duration of influenza A illness when administered within 48 hours of onset of illness.
  - D. Rimantadine and amantadine have identical side effect profiles.
  - E. The most common side effect of amantadine and rimantadine is a generalized macular rash.

**10. Indicate your work setting.**

- A. State/local health department
- B. Other public health setting
- C. Hospital clinic/private practice
- D. Managed care organization
- E. Academic institution
- F. Other

**11. Which best describes your professional activities?**

- A. Patient care — emergency/urgent care department
- B. Patient care — inpatient
- C. Patient care — primary-care clinic
- D. Laboratory/pharmacy
- E. Administration
- F. Public health

**12. I plan to use these guidelines as the basis for . . . (Indicate all that apply.)**

- A. health education materials.
- B. insurance reimbursement policies.
- C. local practice guidelines.
- D. public policy.
- E. other.

**13. Each fall, approximately how many patients do you administer influenza vaccine to?**

- A. None
- B. 1–25
- C. 26–75
- D. 76–125
- E. 126 or more



**14. How much time did you spend reading this report and completing the exam?**

- A. 1–1½ hours
- B. More than 1½ hours but fewer than 2 hours
- C. 2 hours or more

**15. Overall, this report met the stated objectives.**

- A. Strongly agree
- B. Agree
- C. Neither agree nor disagree
- D. Disagree
- E. Strongly disagree

**16. The tables and figures are useful.**

- A. Strongly agree
- B. Agree
- C. Neither agree nor disagree
- D. Disagree
- E. Strongly disagree

**17. Overall, the presentation of the report enhanced my ability to understand the material.**

- A. Strongly agree
- B. Agree
- C. Neither agree nor disagree
- D. Disagree
- E. Strongly disagree

**18. These recommendations will affect my practice.**

- A. Strongly agree
- B. Agree
- C. Neither agree nor disagree
- D. Disagree
- E. Strongly disagree

Answer guide for questions 1-9  
1. A; 2. C; 3. B; 4. D; 5. E; 6. C; 7. D; 8. A; 9. C.

MMWR RESPONSE FORM for CME/CEU/CNE Credit  
MMWR Vol. 48/No. RR-4. April 30, 1999

Prevention and Control of Influenza  
Recommendations of the Advisory Committee  
on Immunization Practices (ACIP)

Fill in the appropriate block(s) to indicate your answer(s).

To receive continuing education credit, you must answer all of the questions.

Detach or photocopy.

- 1.  A  B  C  D  E
- 2.  A  B  C  D  E
- 3.  A  B  C  D
- 4.  A  B  C  D  E
- 5.  A  B  C  D  E
- 6.  A  B  C  D  E
- 7.  A  B  C  D  E
- 8.  A  B  C  D  E
- 9.  A  B  C  D  E
- 10.  A  B  C  D  E  F
- 11.  A  B  C  D  E  F
- 12.  A  B  C  D  E
- 13.  A  B  C  D  E
- 14.  A  B  C
- 15.  A  B  C  D  E
- 16.  A  B  C  D  E
- 17.  A  B  C  D  E
- 18.  A  B  C  D  E

**Please Print:**

Name: \_\_\_\_\_

Address: \_\_\_\_\_  
\_\_\_\_\_

Telephone No.: \_\_\_\_\_ E-mail: \_\_\_\_\_

Fax No.: \_\_\_\_\_

Check one box below:

1.0 hour of CME credit

0.1 hour of CEU credit

1.2 hours of CNE credit


I completed this exam on \_\_\_\_\_  
(date)

**DEPARTMENT OF  
HEALTH AND HUMAN SERVICES**  
Public Health Service  
Centers for Disease Control  
and Prevention (CDC)  
Atlanta, Georgia 30333

**Official Business**  
Penalty for Private Use, \$300



NO POSTAGE  
NECESSARY  
IF MAILED  
IN THE  
UNITED STATES



**BUSINESS REPLY MAIL**

FIRST-CLASS MAIL PERMIT NO. 99110 ATLANTA GA 30333

Postage Will Be Paid by Department of Health and Human Services

MMWR CE CREDIT  
OFFICE OF SCIENTIFIC AND HEALTH COMMUNICATIONS  
EPIDEMIOLOGY PROGRAM OFFICE — MAILSTOP C08  
CENTERS FOR DISEASE CONTROL AND PREVENTION  
1600 CLIFTON ROAD NE  
ATLANTA GEORGIA 30333

Introduction for more information about influenza-associated morbidity and mortality). The potential benefits of influenza vaccination in preventing serious illness, hospitalization, and death greatly outweigh the possible risks for developing vaccine-associated GBS.

The average case-fatality ratio for GBS is 6% and increases with age (89,99). However, no evidence indicates that the case-fatality ratio for GBS differs among vaccinated persons and those not vaccinated.

The incidence of GBS in the general population is very low, but persons with a history of GBS have a substantially greater likelihood of subsequently developing GBS than persons without such a history (90,100). Thus, the likelihood of coincidentally developing GBS after influenza vaccination is expected to be greater among persons with a history of GBS than among persons with no history of this syndrome. Whether influenza vaccination specifically might increase the risk for recurrence of GBS is not known. Therefore, it would seem prudent to avoid influenza vaccination of persons who are not at high risk for severe influenza complications and who are known to have developed GBS within 6 weeks of a previous influenza vaccination. However, many experts believe that for most persons who have a history of GBS and who are at high risk for severe complications from influenza, the established benefits of influenza vaccination justify yearly vaccination.

### **Simultaneous Administration of Other Vaccines, Including Childhood Vaccines**

The target groups for influenza and pneumococcal vaccination overlap considerably (101). For persons at high risk who have not previously been vaccinated with pneumococcal vaccine, health-care providers should strongly consider administering pneumococcal and influenza vaccines concurrently. Both vaccines can be administered at the same time at different sites without increasing side effects (102,103). However, influenza vaccine is administered each year, whereas pneumococcal vaccine is not.

Children at high risk for influenza-related complications can receive influenza vaccine at the same time they receive other routine vaccinations, including pertussis vaccine (DTaP or DTP). Because influenza vaccine can cause fever when administered to young children, DTaP (which is less frequently associated with fever and other adverse events than is DTP) is preferable.

### **Strategies for Implementing These Recommendations in Health-Care Settings**

Successful vaccination programs combine education for health-care workers, publicity and education targeted toward potential recipients, a plan for identifying persons at high risk (usually by medical-record review), and efforts to remove administrative and financial barriers that prevent persons from receiving the vaccine. Persons for whom influenza vaccine is recommended can be identified and vaccinated in the settings described in the following paragraphs.

***Outpatient Facilities Providing Ongoing Care***

Staff in facilities providing ongoing medical care (e.g., physicians' offices, public health clinics, employee health clinics, hemodialysis centers, hospital specialty-care clinics, and outpatient rehabilitation programs) should identify and label the medical records of patients who should receive vaccine. Vaccine should be offered during visits beginning in September and throughout the influenza season. The offer of vaccine and its receipt or refusal should be documented in the medical record. Patients in high-risk groups who do not have regularly scheduled visits during the fall should be reminded by mail or telephone of the need for vaccination.

***Outpatient Facilities Providing Episodic or Acute Care***

Acute health-care facilities (e.g., emergency rooms and walk-in clinics) should offer vaccine to persons in high-risk groups or provide written information on why, where, and how to obtain the vaccine. This written information should be available in languages appropriate for the populations served by the facility.

***Nursing Homes and Other Residential Long-Term Care Facilities***

Vaccination should be routinely provided to all residents of chronic-care facilities with the concurrence of attending physicians. Consent for vaccination should be obtained from the resident or a family member at the time of admission to the facility or anytime afterwards. All residents should be vaccinated at one time, immediately preceding the influenza season. Residents admitted during the winter months after completion of the vaccination program should be vaccinated at the time of admission.

***Acute-Care Hospitals***

All persons aged  $\geq 65$  years and younger persons (including children) with high-risk conditions who are hospitalized at any time from September through March should be offered and strongly encouraged to receive influenza vaccine before they are discharged.

***Visiting Nurses and Others Providing Home Care to Persons at High Risk***

Nursing-care plans should identify patients in high-risk groups, and vaccine should be administered in the home if necessary. Care givers and other persons in the household (including children) should be referred for vaccination.

***Other Facilities Providing Services to Persons Aged  $\geq 65$  Years***

In facilities such as assisted-living facilities, retirement communities, and recreation centers, unvaccinated residents and attendees should be offered vaccine on site before the influenza season. Staff education should emphasize the need for influenza vaccine.

***Other Health-Care Workers***

Before the influenza season, health-care facilities should offer influenza vaccine to all personnel, including night and weekend staff. Particular emphasis should be placed on persons who care for members of high-risk groups.

## **Evolving Developments Related to Influenza Vaccine**

### ***Potential New Vaccines***

Intranasally administered, cold-adapted, live, attenuated, influenza virus vaccines (LAIVs) are being used in Russia and have been under development in the United States since the 1960s (104–108). The viruses in these vaccines replicate in the upper respiratory tract and elicit a specific protective immune response. LAIVs have been studied as monovalent, bivalent, and trivalent formulations (107,108). LAIVs consist of live virus strains that induce minimal symptoms (i.e., attenuated) and that replicate poorly at temperatures found in the lower respiratory tract (i.e., temperature sensitive). The potential advantages of LAIVs are their ability to induce a broad mucosal and systemic immune response, ease of administration, and the acceptability of an intranasal route of administration compared with injectable vaccines.

In a 5-year study that compared trivalent inactivated vaccine and bivalent LAIV (administered by nose drops) and that used related but different vaccine strains, the two vaccines were found to be approximately equivalent in terms of effectiveness (109). In a recent study of children aged 15–71 months, an intranasally administered trivalent LAIV was 93% effective in preventing culture-positive influenza A (H3N2) and B infections, reduced otitis media among vaccinated children by 30%, and reduced otitis media with concomitant antibiotic use by 35% (13). In a follow-up study during the 1997–1998 season, the trivalent LAIV was 86% effective in preventing culture-positive influenza in children, despite a poor match between the vaccine's influenza A (H3N2) component and the predominant circulating influenza A (H3N2) virus (110). No study has directly compared the effectiveness or efficacy of trivalent inactivated vaccine and trivalent LAIV.

### ***Potential Expansion of Groups Recommended for Vaccination***

During 1998, the ACIP formed a working group to explore issues related to the potential expansion of recommendations for the use of influenza vaccine. These discussions were started because a) the impact of influenza might decline because of the development and potential combined use of new influenza vaccines, antiviral agents, and commercial rapid detection kits; b) the risk of influenza-related hospitalizations might be substantially increased among healthy children aged <5 years compared with older children (Influenza Branch, DVRD, NCID, CDC, unpublished data, 1999; Marie R. Griffin, M.D., M.P.H., Vanderbilt University Medical Center, unpublished data, 1999); and c) a substantial cost benefit might result from vaccinating groups such as healthy young adults, who traditionally are not considered to be at high risk for influenza-related complications.

#### ***Young Children***

Several studies indicate that rates of hospitalizations are higher among young children than older children when influenza viruses are in circulation (26,27,111,112). The increased rates for hospitalizations are comparable with rates for other high-risk groups. However, the interpretation of these findings has been confounded by cocirculation of respiratory syncytial viruses, which are a major cause of serious respiratory viral morbidity among children and which frequently circulate during the same time as influenza viruses (113–115). Recent unpublished studies have been

undertaken to separate the effects of respiratory syncytial viruses and influenza viruses on rates of hospitalizations among children aged <5 years who do not have high-risk conditions. If these and other studies indicate that the risk of hospitalizations from influenza is increased among young and healthy children, then the ACIP will consider extending vaccine recommendations to this group after the logistic and economic consequences of such a recommendation are adequately addressed.

#### ***Adults Aged 50–64 Years***

Rates of influenza-related hospitalizations and mortality among persons aged 50–64 years suggest that this group might be at increased risk for influenza-related complications (5–7,24,116). The prevalence of chronic medical conditions is higher in this group than among younger adults. However, further studies of this age group are needed to clarify the risks for complications from influenza and to document the potential impact of recommending routine influenza vaccination for this group.

## **RECOMMENDATIONS FOR THE USE OF ANTIVIRAL AGENTS FOR INFLUENZA A**

Antiviral drugs for influenza are an important adjunct to influenza vaccine for the control and prevention of influenza. The currently licensed agents are amantadine hydrochloride and rimantadine hydrochloride, which are chemically related antiviral drugs with specific activity against influenza A viruses but not influenza B viruses. Amantadine was approved in 1976 for the treatment and prophylaxis of influenza type A virus infections in adults and children aged  $\geq 1$  year. Rimantadine was approved in 1993 for treatment and prophylaxis of infection in adults. Although rimantadine was approved only for prophylaxis of infection in children, many experts consider it appropriate for treatment among children. Another class of antiviral agents with activity against both influenza A and B viruses is under development and testing (see *Evolving Developments Related to Influenza Antiviral Agents*).

Amantadine and rimantadine differ in terms of pharmacokinetics, side effects, and costs. In particular, rimantadine is associated with fewer central nervous system side effects than amantadine (117,118), but it is more expensive.

### **Indications for Use**

Amantadine and rimantadine are indicated for the prophylaxis and treatment of influenza A infection. When administered prophylactically to healthy adults or children, both drugs are approximately 70%–90% effective in preventing illness from influenza A infection. When used as prophylaxis, one benefit of these antiviral agents is that they can prevent illness while permitting subclinical infection. Therefore, some persons who take these drugs will develop protective immune responses to circulating influenza viruses. When administered as treatment within 48 hours of illness onset in healthy adults, amantadine and rimantadine can reduce the severity and duration of signs and symptoms of influenza A illness. Studies of the efficacy of either amantadine or rimantadine treatment in children are limited.

## Role of Viral Diagnosis

The appropriate treatment of patients with viral respiratory illness depends on accurate and timely diagnosis. The early diagnosis of influenza also can help reduce the inappropriate use of antibiotics, a growing major public health problem. Currently, several commercial assays are available that can be used in a clinic setting to rapidly (30 minutes or less) detect influenza viruses, and additional commercial assays are available for use by laboratories. No published study has directly compared the sensitivity, specificity, positive predictive value, and negative predictive value of these assays for detecting influenza in clinical specimens.

The use of viral culture, in addition to rapid diagnostic tests, remains critical, because only cultures yield viruses that can be characterized to provide specific information on circulating influenza subtypes and strains. This information is needed to assess the match between current circulating and vaccine strains and to help formulate vaccine for the coming year.

## Administration of Amantadine and Rimantadine

### *Use for Prophylaxis*

Chemoprophylaxis is not a substitute for vaccination. When amantadine or rimantadine is administered as prophylaxis, factors related to cost, compliance, and potential side effects should be considered when determining the period of prophylaxis. To be maximally effective as prophylaxis, the drug must be taken each day for the duration of influenza activity in the community. However, to be most cost-effective, amantadine or rimantadine prophylaxis should be taken only during the period of peak influenza activity in a community.

### ***Persons at High Risk Who Are Vaccinated After Influenza Activity Has Begun***

Persons at high risk for complications of influenza still can be vaccinated after an outbreak of influenza A has begun in a community. However, the development of antibodies in adults after vaccination can take as long as 2 weeks (119,120). In this situation, chemoprophylaxis should be considered for such persons during the time from vaccination until immunity has developed. Children who receive influenza vaccine for the first time can require as long as 6 weeks of prophylaxis (i.e., prophylaxis for 2 weeks after the second dose of vaccine has been received). Amantadine and rimantadine do not interfere with the antibody response to the vaccine (121).

### ***Persons Who Provide Care to Those at High Risk***

During community or institutional outbreaks, chemoprophylaxis during peak influenza activity can be considered for unvaccinated persons who have frequent contact with persons at high risk to reduce the spread of virus to persons at high risk. Persons with frequent contact include household members, visiting nurses, volunteer workers, and employees of hospitals, clinics, and chronic-care facilities. If the outbreak is caused by a variant strain of influenza A that might not be controlled by the vaccine, chemoprophylaxis should be considered for all such persons, regardless of their vaccination status.



***Persons Who Have Immune Deficiency***

Chemoprophylaxis can be considered for persons at high risk who are expected to have an inadequate antibody response to influenza vaccine. This category includes persons infected with human immunodeficiency virus (HIV), especially those with advanced HIV disease. No published data are available concerning possible efficacy of chemoprophylaxis among persons with HIV infection or interactions with other drugs used to manage HIV infection. Such patients should be monitored closely if amantadine or rimantadine chemoprophylaxis is administered.

***Other Persons***

Chemoprophylaxis throughout the influenza season or during peak influenza activity might be appropriate for persons at high risk who should not be vaccinated. Amantadine or rimantadine also can be administered prophylactically to persons who wish to avoid influenza A illness. Health-care providers and patients should make this decision on an individual basis.

***Use for Treatment***

Amantadine and rimantadine can reduce the severity and shorten the duration of influenza A illness among healthy adults when administered within 48 hours of illness onset (121). Whether antiviral therapy will prevent complications of influenza type A among persons at high risk is unknown. Among children, rimantadine is approved for prophylaxis only, although many experts believe rimantadine is also appropriate for therapy.

To reduce the emergence of antiviral drug-resistant viruses, treatment of persons who have influenza-like illness should be discontinued as soon as clinically warranted, generally after 3–5 days of treatment or within 24–48 hours after the disappearance of signs and symptoms.

***Use for the Control of Influenza Outbreaks in Institutions***

Most published reports on the use of antiviral drugs to control institutional outbreaks of influenza are based on studies of nursing home populations. When confirmed or suspected outbreaks of influenza A occur in institutions that house persons at high risk, chemoprophylaxis should be started as early as possible to reduce the spread of the virus. In these situations, having preapproved orders from physicians or plans to obtain orders for antiviral medications on short notice is extremely useful.

When institutional outbreaks occur, chemoprophylaxis should be administered to all residents — regardless of whether they received influenza vaccine during the previous fall — and continued for at least 2 weeks or until approximately 1 week after the end of the outbreak. The individual dosage for each resident should be determined. Chemoprophylaxis also can be offered to unvaccinated staff who provide care to persons at high risk. Prophylaxis should be considered for all employees, regardless of their vaccination status, if the outbreak is caused by a variant strain of influenza A that is not well matched by the vaccine. Chemoprophylaxis also can be considered for controlling influenza A outbreaks in other closed or semiclosed settings (e.g., dormitories or other settings where persons live in close proximity).

Whenever any institutional outbreak occurs, measures should be taken to reduce contact as much as possible between persons taking antiviral drugs for treatment and other persons, including those taking chemoprophylaxis, to limit the potential transmission of drug-resistant virus.

### **Dosage**

Dosage recommendations vary by age group (Table 2).

#### **Children**

**Amantadine.** The use of amantadine among children aged <1 year has not been adequately evaluated. The U.S. Food and Drug Administration-approved dosage for children aged 1–9 years is 4.4–8.8 mg/kg/day, not to exceed 150 mg/day. Although further studies are needed to determine the optimal dosage for children aged 1–9 years, physicians should consider prescribing only 5 mg/kg/day (not to exceed 150 mg/day) to reduce the risk for toxicity. The approved dosage for children aged ≥10 years is 200 mg/day; however, for children weighing <40 kg, prescribing 5 mg/kg/day, regardless of age, is advisable.

**Rimantadine.** The use of rimantadine among children aged <1 year has not been adequately evaluated. For children aged 1–9 years, rimantadine should be administered in one or two divided doses at a dosage of 5 mg/kg/day, not to exceed 150 mg/day. The approved dosage for children aged ≥10 years is 200 mg/day (100 mg twice a day); however, for children weighing <40 kg, prescribing 5 mg/kg/day, regardless of age, also is recommended.

#### **Persons Aged ≥65 Years**

**Amantadine.** The daily dose of amantadine for persons aged ≥65 years should not exceed 100 mg for prophylaxis or treatment, because renal function declines with increasing age. For some elderly persons, the dose should be further reduced.

**Rimantadine.** Among elderly persons, the incidence and severity of central nervous system (CNS) side effects are substantially lower among those taking rimantadine at a dosage of 100 mg/day than among those taking amantadine at dosages adjusted for estimated renal clearance (117). However, chronically ill elderly persons have had a higher incidence of CNS and gastrointestinal symptoms and twofold to fourfold higher serum concentrations than healthy, younger persons when rimantadine has been administered at a dosage of 200 mg/day (121).

For elderly nursing home residents, the dosage of rimantadine should be reduced to 100 mg/day for prophylaxis or treatment. For other elderly persons, further studies are needed to determine the optimal dosage. However, a reduction in dosage to 100 mg/day should be considered for all persons aged ≥65 years who experience side effects when taking a dosage of 200 mg/day.

#### **Persons With Impaired Renal Function**

**Amantadine.** A reduction in dosage is recommended for patients with creatinine clearance ≤50 mL/min/1.73m<sup>2</sup>. Guidelines for amantadine dosage based on creatinine clearance are found in the packet insert. Because recommended dosages based on creatinine clearance might provide only an approximation of the optimal dose for a

**TABLE 2. Recommended daily dosage for amantadine and rimantadine treatment and prophylaxis**

Antiviral agent	Age group			
	1–9 yrs	10–13 yrs	14–64 yrs	≥65 yrs
<b>Amantadine*</b>				
Treatment	5 mg/kg/day up to 150 mg <sup>†</sup> in two divided doses	100 mg twice daily <sup>§</sup>	100 mg twice daily	≤100 mg/day
Prophylaxis	5 mg/kg/day up to 150 mg <sup>†</sup> in two divided doses	100 mg twice daily <sup>§</sup>	100 mg twice daily	≤100 mg/day
<b>Rimantadine<sup>¶</sup></b>				
Treatment	NA	NA	100 mg twice daily	100 or 200** mg/day
Prophylaxis	5 mg/kg/day up to 150 mg <sup>†</sup> in two divided doses	100 mg twice daily <sup>§</sup>	100 mg twice daily	100 or 200** mg/day

NOTE: Amantadine manufacturers include Endo Pharmaceuticals (Symmetrel<sup>®</sup>—tablet and syrup); Invamed and Rosemont (Amantadine HCL—capsule); and Alpharma, Copley Pharmaceutical, HiTech Pharma, Mikart, Morton Grove, and Pharmaceutical Associates (Amantadine HCL—syrup). Rimantadine is manufactured by Forest Laboratories (Flumadine<sup>®</sup>—tablet and syrup).

\*The drug package insert should be consulted for dosage recommendations for administering amantadine to persons with creatinine clearance ≤50 mL/min/1.73m<sup>2</sup>.

<sup>†</sup>5 mg/kg of amantadine or rimantadine syrup = 1 tsp/22 lbs.

<sup>§</sup>Children ≥10 years of age who weigh <40 kg should be administered amantadine or rimantadine at a dosage of 5 mg/kg/day.

<sup>¶</sup>A reduction in dosage to 100 mg/day of rimantadine is recommended for persons who have severe hepatic dysfunction or those with creatinine clearance ≤10 mL/min. Other persons with less severe hepatic or renal dysfunction taking >100 mg/day of rimantadine should be observed closely, and the dosage should be reduced or the drug discontinued, if necessary.

\*\*Elderly nursing-home residents should be administered only 100 mg/day of rimantadine. A reduction in dosage to 100 mg/day should be considered for all persons ≥65 years of age if they experience possible side effects when taking 200 mg/day.

NA=Not applicable.

given patient, such persons should be observed carefully for adverse reactions. If necessary, further reduction in the dose or discontinuation of the drug might be indicated because of side effects. Hemodialysis contributes minimally to amantadine clearance (122).

**Rimantadine.** A reduction in dosage to 100 mg/day is recommended for persons with creatinine clearance ≤10 mL/min. Because of the potential for accumulation of rimantadine and its metabolites, patients with any degree of renal insufficiency, including elderly persons, should be monitored for adverse effects, and either the dosage should be reduced or the drug should be discontinued, if necessary. Hemodialysis contributes minimally to drug clearance (123).

**Persons With Liver Disease**

**Amantadine.** No increase in adverse reactions to amantadine has been observed among persons with liver disease. Rare instances of reversible elevation of liver enzymes in patients receiving amantadine have been reported, although a specific relationship between the drug and such changes has not been established (124).

**Rimantadine.** A dosage reduction to 100 mg/day is recommended for persons with severe hepatic dysfunction.

**Persons With Seizure Disorders**

**Amantadine.** An increased incidence of seizures has been reported among patients with a history of seizure disorders who have received amantadine (125). Patients with seizure disorders should be observed closely for possible increased seizure activity when taking amantadine.

**Rimantadine.** Seizures (or seizure-like activity) have been reported among persons with a history of seizures who were not receiving anticonvulsant medication while taking rimantadine (126). The extent to which rimantadine might increase the incidence of seizures among persons with seizure disorders has not been adequately evaluated.

**Route**

Amantadine and rimantadine are administered orally. Both antiviral drugs are available in tablet or syrup form.

**Pharmacokinetics**

Despite their similarities, amantadine and rimantadine differ substantially in their pharmacokinetic properties. More than 90% of amantadine is excreted unchanged in the urine by glomerular filtration and tubular secretion (127–131). Thus, renal clearance of amantadine is reduced substantially in persons with renal insufficiency, and dosages might need to be decreased (see Dosage) (Table 2).

Approximately 75% of rimantadine is metabolized by the liver (132). The safety and pharmacokinetics of rimantadine among persons with liver disease have been evaluated only after single-dose administration (132,133). In a study of persons with chronic liver disease (most with stabilized cirrhosis), no alterations in liver function were observed after a single dose (132,133). However, for persons with severe liver dysfunction, the apparent clearance of rimantadine was 50% lower than that reported for persons without liver disease (134).

Rimantadine and its metabolites are excreted by the kidneys. The safety and pharmacokinetics of rimantadine among patients with renal insufficiency have been evaluated only after single-dose administration (123,132). Further studies are needed to determine multiple-dose pharmacokinetics and the most appropriate dosages for patients with renal insufficiency. In a single-dose study of patients with anuric renal failure, the apparent clearance of rimantadine was approximately 40% lower, and the elimination half-life was approximately 1.6-fold greater than that in healthy persons of the same age (123). Hemodialysis did not contribute to drug clearance. In studies of persons with less severe renal disease, drug clearance was also reduced, and plasma concentrations were higher than those among control patients without renal disease who were the same weight, age, and sex (134,135).

## Side Effects and Adverse Reactions

Both amantadine and rimantadine can cause CNS and gastrointestinal side effects when administered to young, healthy adults at equivalent dosages of 200 mg/day. However, the incidence of CNS side effects (e.g., nervousness, anxiety, difficulty concentrating, and lightheadedness) is higher among persons taking amantadine than among those taking rimantadine (118). In a 6-week study of prophylaxis among healthy adults, approximately 6% of participants taking rimantadine at a dosage of 200 mg/day experienced at least one CNS symptom, compared with approximately 13% of those taking the same dosage of amantadine and 4% of those taking placebo (118). Gastrointestinal side effects (e.g., nausea and anorexia) occur in approximately 1%–3% of persons taking either drug, compared with 1% of persons receiving the placebo (118).

Side effects associated with both drugs are usually mild and cease soon after discontinuing the drug. Side effects can diminish or disappear after the first week, despite continued drug ingestion. However, serious side effects have been observed (e.g., marked behavioral changes, delirium, hallucinations, agitation, and seizures) (125). These more severe side effects have been associated with high plasma drug concentrations and have been observed most often among persons who have renal insufficiency, seizure disorders, or certain psychiatric disorders and among elderly persons who have been taking amantadine as prophylaxis at a dosage of 200 mg/day (131). Clinical observations and studies have indicated that lowering the dosage of amantadine among these persons reduces the incidence and severity of such side effects (Table 2). Because rimantadine has been marketed for a shorter period than amantadine, its safety in certain patient populations (e.g., chronically ill and elderly persons) has been evaluated less frequently.

The patient's age, weight, and renal function; the presence of other medical conditions; indications for the use of amantadine or rimantadine (i.e., prophylaxis or therapy); and the potential for interaction with other medications must be considered, and the dosage and duration of treatment must be adjusted appropriately. Modifications in dosage might be required for persons who have impaired renal or hepatic function, persons aged  $\geq 65$  years, children, and persons with a history of seizures (Table 2).

## Drug Interactions

Careful observation is advised when amantadine is administered concurrently with drugs that affect the CNS, especially CNS stimulants. Concomitant administration of antihistamines or anticholinergic drugs can increase the incidence of adverse CNS reactions (121).

No clinically significant interactions between rimantadine and other drugs have been identified. For more detailed information concerning potential drug interactions for either amantadine or rimantadine, the package inserts should be consulted.

## Antiviral Drug-Resistant Strains of Influenza

Amantadine-resistant viruses are cross-resistant to rimantadine and vice versa (136). Drug-resistant viruses can appear in up to approximately one third of patients

when either amantadine or rimantadine is used for therapy (137,138). During the course of therapy, antiviral-resistant influenza strains can replace sensitive strains within 2–3 days of starting therapy (138,139). Resistant viruses have been isolated from persons who live at home or in an institution where other residents are taking or have recently taken amantadine or rimantadine as therapy (140,141); however, the frequency with which resistant viruses are transmitted and their impact on efforts to control influenza are unknown. Amantadine- and rimantadine-resistant viruses are no more virulent or transmissible than sensitive viruses (142). The screening of epidemic strains of influenza A has rarely detected amantadine- and rimantadine-resistant viruses (138,143).

Persons who have influenza A infection and who are treated with either drug can shed sensitive viruses early in the course of treatment and later shed drug-resistant viruses, especially after 5–7 days of therapy (137). Such persons can benefit from therapy even when resistant viruses emerge. Influenza isolates obtained from persons who are receiving amantadine or rimantadine should be reported to CDC through state health departments, and the isolates should be sent to CDC for antiviral sensitivity testing.

## **Evolving Developments Related to Antiviral Agents for Influenza**

The currently available antiviral drugs rimantadine and amantadine are effective only for influenza A viruses. Another class of influenza antiviral drugs, neuraminidase inhibitors, which selectively inhibit both influenza A and B viruses, is under development and testing. Neuraminidase inhibitors are sialic acid analogues (144). Recent studies have found neuraminidase inhibitors to be 67%–82% effective in preventing laboratory-confirmed infection when administered as prophylaxis (144,145) and to reduce the duration of illness by 1–1.5 days when started within 36–48 hours of illness onset. (146,147). The reported adverse effects of these drugs are substantially different from amantadine and rimantadine; in particular, the drugs do not appear to affect the central nervous system (147). Currently, both intranasal spray/inhalation and oral forms of these drugs are undergoing testing, but neither has yet been licensed by the U.S. Food and Drug Administration.

## **SOURCES OF INFORMATION ON INFLUENZA AND ITS SURVEILLANCE**

Information regarding influenza surveillance is available through the CDC Voice Information System (influenza update), (888) 232-3228; CDC Fax Information Service, (888) 232-3299; or website for the Influenza Branch, DVRD, NCID, CDC at <<http://www.cdc.gov/ncidod/diseases/flu/weekly.htm>>. From October through May, the information is updated at least every other week. In addition, periodic updates about influenza are published in the weekly *MMWR*. State and local health departments should be consulted regarding availability of influenza vaccine, access to vaccination programs, information about state or local influenza activity, and for reporting influenza outbreaks and receiving advice regarding their control.

### Acknowledgment

The authors thank Amanda Crowell of CDC's Epidemiology Program Office (Office of Scientific and Health Communication) for assistance in editing references for this report.

### References

1. Simonsen L, Schonberger LB, Stroup DF, Arden NH, Cox NJ. The impact of influenza on mortality in the USA. In: Brown LE, Hampson AW, Webster RG, eds. Options for the control of influenza III. Amsterdam: Elsevier Science BV, 1996:26–33.
2. Lui K-J, Kendal AP. Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. *Am J Public Health* 1987;77:712–6.
3. Monto AS, Kioumeh F. The Tecumseh study of respiratory illness. IX. Occurrence of influenza in the community, 1966–1971. *Am J Epidemiol* 1975;102:553–63.
4. Glezen WP, Couch RB. Interpandemic influenza in the Houston area, 1974–76. *N Engl J Med* 1978;298:587–92.
5. Barker WH. Excess pneumonia and influenza associated hospitalization during influenza epidemics in the United States, 1970–78. *Am J Public Health* 1986;76:761–5.
6. Barker WH, Mullooly JP. Impact of epidemic type A influenza in a defined adult population. *Am J Epidemiol* 1980;112:798–811.
7. Glezen WP. Serious morbidity and mortality associated with influenza epidemics [Review]. *Epidemiol Rev* 1982;4:25–44.
8. CDC. Influenza and pneumococcal vaccination coverage levels among persons aged  $\geq 65$  years. *MMWR* 1995;44:506–7,513–5.
9. CDC. Influenza and pneumococcal vaccination levels among adults aged  $\geq 65$  years. *MMWR* 1998;47:797–802.
10. Public Health Service. Healthy people 2000: national health promotion and disease prevention objectives — full report, with commentary. Washington, DC: US Department of Health and Human Services, Public Health Service, 1991; DHHS publication no. (PHS)91-50212.
11. CDC. Implementation of the Medicare influenza vaccination benefit—United States, 1993. *MMWR* 1994; 43:771–3.
12. Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. *N Engl J Med* 1995;333:889–93.
13. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. *N Engl J Med* 1998;338:1405–12.
14. Clements DA, Langdon L, Bland C, Walter E. Influenza A vaccine decreases the incidence of otitis media in 6- to 30-month-old children in day care. *Arch Pediatr Adolesc Med* 1995; 149:1113–7.
15. Heikkinen T, Ruuskanen O, Waris M, Ziegler T, Arola M, Halonen P. Influenza vaccination in the prevention of acute otitis media in children. *Am J Dis Child* 1991;145:445–8.
16. Walker FJ, Singleton JA, Greby SM, Strikas RA. Influenza and pneumococcal vaccination of adults aged 18–64 years, United States, 1995 [Abstract]. In: Abstracts of the 33rd National Immunization Conference. Atlanta, GA: CDC, 1999 (in press).
17. Kramarz P, DeStefano F, Gargiullo P, Chen R, Vaccine Safety Datalink Team. Determinants of influenza vaccination in children with asthma in four health maintenance organizations [Abstract]. 1998 Epidemic Intelligence Service Conference. Atlanta, GA: CDC, 1998.
18. Murphy BR, Webster RG. Orthomyxoviruses. In: Fields BN, Knipe DM, Howley PM, et al, eds. *Fields virology*, Third edition. Philadelphia, PA: Lippincott-Raven Publishers, 1996;1397–445.
19. Clements ML, Betts RF, Tierney EL, Murphy BR. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. *J Clin Microbiol* 1986;24:157–60.
20. Couch RB, Kasel JA. Immunity to influenza in man [Review]. *Annu Rev Microbiol* 1983;37: 529–49.
21. Nicholson KG. Clinical features of influenza. *Semin Respir Infect* 1992;7:26–37.
22. Noble GR. Epidemiological and clinical aspects of influenza. In: Beare AS, ed. *Basic and applied influenza research*. Boca Raton, FL: CRC Press, 1982:11–50.
23. Eickhoff TC, Sherman IL, Serfling RE. Observations on excess mortality associated with epidemic influenza. *JAMA* 1961;176:776–82.

24. Barker WH, Mullooly JP. Pneumonia and influenza deaths during epidemics: implications for prevention. *Arch Intern Med* 1982;142:85-9.
25. Lui K-J, Kendal AP. Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. *Am J Public Health* 1987;77:712-6.
26. Glezen WP, Decker M, Perrotta DM. Survey of underlying conditions of persons hospitalized with acute respiratory disease during influenza epidemics in Houston, 1978-1981. *Am Rev Resp Dis* 1987;136:550-5.
27. Glezen WP. Influenza surveillance in an urban area. *Can J Infect Dis* 1993;4:272-4.
28. Simonsen L, Clarke MJ, Williamson GD, Stroup DF, Arden NH, Schonberger LB. The impact of influenza epidemics on mortality: introducing a severity index. *Am J Public Health* 1997; 87:1944-50.
29. Simonsen L, Clarke MJ, Schonberger LB, Arden NA, Cox NJ, Fukuda K. Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. *J Infect Dis* 1998;178: 53-60.
30. National Center for Health Statistics. Health, United States, 1998. Hyattsville, MD: National Center for Health Statistics, 1998.
31. Patriarca PA, Weber JA, Parker RA, et al. Risk factors for outbreaks of influenza in nursing homes: a case-control study. *Am J Epidemiol* 1986;124:114-9.
32. Kilbourne ED. Influenza. New York, NY: Plenum Medical Book Company, 1987.
33. La Montagne JR, Noble GR, Quinnan GV, et al. Summary of clinical trials of inactivated influenza vaccine-1978. *Rev Infect Dis* 1983;5:723-36.
34. Oxford JS, Schild GC, Potter CW, Jennings R. The specificity of the anti-haemagglutinin antibody response induced in man by inactivated influenza vaccine and by natural infection. *J Hygiene* 1979;82:51-61.
35. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. *Br Med Bull* 1979;35:69-75.
36. Hirota Y, Kaji M, Ide S, et al. Antibody efficacy as a keen index to evaluate influenza vaccine effectiveness. *Vaccine* 1997;15:962-7.
37. Blumberg EA, Albano C, Pruett T, et al. The immunogenicity of influenza virus vaccine in solid organ transplant recipients. *Clin Infect Dis* 1996;22:295-302.
38. Dorrell L, Hassan I, Marshall S, Chakraverty P, Ong E. Clinical and serological responses to an inactivated influenza vaccine in adults with HIV infection, diabetes, obstructive airways disease, elderly adults and healthy volunteers. *Int J STD AIDS* 1997;8:776-9.
39. McElhaney JE, Beattie BL, Devine R, Grynoch R, Toth EL, Bleackly RC. Age-related decline in interleukin 2 production in response to influenza vaccine. *J Am Geriatr Soc* 1990;38:652-8.
40. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature. *Ann Intern Med* 1995; 123: 518-27.
41. Mullooly JP, Bennett MD, Hornbrook MC, et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. *Ann Intern Med* 1994; 121:947-52.
42. Palache AM. Influenza vaccine: a reappraisal of their use. *Drugs* 1997;54:841-56.
43. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. *N Engl J Med* 1994;331:778-84.
44. Patriarca PA, Weber JA, Parker RA, et al. Efficacy of influenza vaccine in nursing homes: reduction in illness and complications during an influenza A (H3N2) epidemic. *JAMA* 1985; 253:1136-9.
45. Arden NH, Patriarca PA, Kendal AP. Experiences in the use and efficacy of inactivated influenza vaccine in nursing homes. In: Kendal AP, Patriarca PA, eds. Options for the control of influenza. New York, NY: Alan R. Liss Inc., 1986:155-68.
46. Noble GR. Epidemiological and clinical aspects of influenza. In: Beare AS, ed. Basic and applied influenza research. Boca Raton, FL: CRC Press, 1982:41-2.
47. Harris JW. Influenza occurring in pregnant women: a statistical study of thirteen hundred and fifty cases. *JAMA* 1919;72:978-80.
48. Widelock D, Csizmas L, Klein S. Influenza, pregnancy, and fetal outcome. *Public Health Rep* 1963;78:1-11.



49. Freeman DW, Barno A. Deaths from Asian influenza associated with pregnancy. *Am J Obstet Gynecol* 1959;78:1172–5.
50. Shahab SZ, Glezen WP. Influenza virus. In: Gonik B, ed. *Viral diseases in pregnancy*. New York, NY: Springer-Verlag, 1994:215–23.
51. Schoenbaum SC, Weinstein L. Respiratory infection in pregnancy. *Clin Obstet Gynecol* 1979; 22:293–300.
52. Kirshon B, Faro S, Zurawin RK, Samo TC, Carpenter RJ. Favorable outcome after treatment with amantadine and ribavirin in a pregnancy complicated by influenza pneumonia: a case report. *J Reprod Med* 1988;33:399–401.
53. Kort BA, Cefalo RC, Baker VV. Fatal influenza A pneumonia in pregnancy. *Am J Perinatol* 1986; 3:179–82.
54. Neuzil KM, Reed GW, Mitchel EF, Simonsen L, Griffin MR. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. *Am J Epidemiol* 1998;148:1094–102.
55. Heinonen OP, Shapiro S, Monson RR, Hartz SC, Rosenberg L, Slone D. Immunization during pregnancy against poliomyelitis and influenza in relation to childhood malignancy. *Int J Epidemiol* 1973;2:229–35.
56. Couch RB. Editorial response: influenza, influenza virus vaccine, and human immunodeficiency virus infection. *Clin Infect Dis* 1999;28:548–51.
57. Neuzil KM, Reed GW, Mitchel EF, Griffin MR. Influenza-associated morbidity and mortality in young and middle-aged women. *JAMA* 1999;281:901–7.
58. Safrin S, Rush JD, Mills J. Influenza in patients with human immunodeficiency virus infection. *Chest* 1990;98:33–7.
59. Radwan H, Ellison R. Severe influenza pneumonia in HIV patients during 1997–1998 influenza season. Presented as a poster at Infectious Diseases Society of America 36th Annual Meeting. Alexandria, VA: Infectious Diseases Society of America, 1998.
60. Chadwick EG, Chang G, Decker MD, Yogev R, Dimichele D, Edwards KM. Serologic response to standard inactivated influenza vaccine in human immunodeficiency virus-infected children. *Pediatr Infect Dis J* 1994;13:206–11.
61. Huang K-L, Ruben FL, Rinaldo CR, Kingsley L, Lyter DW, Ho M. Antibody responses after influenza and pneumococcal immunization in HIV-infected homosexual men. *JAMA* 1987; 257:2047–50.
62. Staprans SI, Hamilton BL, Follansbee SE, et al. Activation of virus replication after vaccination of HIV-1-infected individuals. *J Exp Med* 1995;182:1727–37.
63. Kroon FP, van Dissel JT, de Jong JC, van Furth R. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. *AIDS* 1994;8:469–76.
64. Miotti PG, Nelson KE, Dallabetta GA, Farzadegan H, Margolick J, Clements ML. The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. *JAMA* 1989;262:779–83.
65. Ho DD. HIV-1 viraemia and influenza. *Lancet* 1992;339:1549.
66. O'Brien WA, Grovit-Ferbas K, Namazi A, et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. *Blood* 1995;86:1082–9.
67. Glesby MJ, Hoover DR, Farzadegan H, Margolick JB, Saah AJ. The effect of influenza vaccination on human immunodeficiency virus type 1 load: a randomized, double-blind, placebo-controlled study. *J Infect Dis* 1996;174:1332–6.
68. Fowke KR, D'Amico R, Chernoff DN, et al. Immunologic and virologic evaluation after influenza vaccination of HIV-1-infected patients. *AIDS* 1997;11:1013–21.
69. Fuller JD, Craven DE, Steger KA, Cox N, Heeren TC, Chernoff D. Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response. *Clin Infect Dis* 1999;28:541–7.
70. Cate TR, Couch RB, Parker D, Baxter B. Reactogenicity, immunogenicity, and antibody persistence in adults given inactivated influenza virus vaccines—1978. *Rev Infect Dis* 1983; 5:737–47.
71. Künzel W, Glathe H, Engelmann H, Van Hoecke C. Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine in subjects previously vaccinated or vaccinated for the first time. *Vaccine* 1996;14:1108–10.

72. Gross PA, Weksler ME, Quinnan GV Jr, Douglas RG Jr, Gaerlan PF, Denning CR. Immunization of elderly people with two doses of influenza vaccine. *J Clin Microbiol* 1987;25:1763-5.
73. Iorio AM, Alatri A, Francisci D, et al. Immunogenicity of influenza vaccine (1993-94 winter season) in HIV-seropositive and -seronegative ex-intravenous drug users. *Vaccine* 1997;15:97-102.
74. Feery BJ, Cheyne IM, Hampson AW, Atkinson MIE. Antibody response to one and two doses of influenza virus subunit vaccine. *Med J Aust* 1976;1:186, 188-9.
75. Howells CHL, Evans AD, Vesselinova-Jenkins C. Effect of two doses of influenza vaccine in stimulating antibody in volunteers. *Lancet* 1973;1:1436-8.
76. CDC. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 1994;43(No. RR-1):1-36.
77. Govaert ME, Dinant GJ, Aretz K, Masurel N, Sprenger MJW, Knottnerus JA. Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial. *BMJ* 1993;307:988-90.
78. Margolis KL, Nichol KL, Poland GA, Pluhar RE. Frequency of adverse reactions to influenza vaccine in the elderly: a randomized, placebo-controlled trial. *JAMA* 1990;264:1139-41.
79. Nichol KL, Margolis KL, Lind A, et al. Side effects associated with influenza vaccination in healthy working adults: a randomized, placebo-controlled trial. *Arch Intern Med* 1996;156:1546-50.
80. Scheifele DW, Bjornson G, Johnson J. Evaluation of adverse events after influenza vaccination in hospital personnel. *Can Med Assoc J* 1990;142:127-30.
81. Barry DW, Mayner RE, Hochstein HD, et al. Comparative trial of influenza vaccine. II. Adverse reactions in children and adults. *Am J Epidemiol* 1976;104:47-59.
82. Bierman CW, Shapiro GG, Pierson WE, Taylor JW, Foy HM, Fox JP. Safety of influenza vaccination in allergic children. *J Infect Dis* 1997;136:S652-S655.
83. James JM, Zeiger RS, Lester MR, et al. Safe administration of influenza vaccine to patients with egg allergy. *J Pediatr* 1998;133:624-8.
84. Murphy KR, Strunk RC. Safe administration of influenza vaccine in asthmatic children hypersensitive to egg proteins. *J Pediatr* 1985;106:931-3.
85. Aberer W. Vaccination despite thimerosal sensitivity. *Contact Dermatitis* 1991;24:6-10.
86. Kirkland LR. Ocular sensitivity to thimerosal: A problem with hepatitis B vaccine? *South Med J* 1990;83:497-9.
87. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. *Am J Epidemiol* 1979;110:105-23.
88. Safranek TJ, Lawrence DN, Kurland LT, et al. Reassessment of the association between Guillain-Barre syndrome and receipt of swine influenza vaccine in 1976-1977: results of a two-state study. Expert Neurology Group. *Am J Epidemiol* 1991;133:940-51.
89. Ropper AH. The Guillain-Barré syndrome. *N Engl J Med* 1992;326:1130-6.
90. Hurwitz ES, Schonberger LB, Nelson DB, Holman RC. Guillain-Barré syndrome and the 1978-1979 influenza vaccine. *N Engl J Med* 1981;304:1557-61.
91. Kaplan JE, Katona P, Hurwitz ES, Schonberger LB. Guillain-Barré syndrome in the United States, 1979-1980 and 1980-1981. *JAMA* 1982;248:698-700.
92. Chen R, Kent J, Rhodes P, Simon P, Schonberger L. Investigation of a possible association between influenza vaccination and Guillain-Barré syndrome in the United States, 1990-1991 [Abstract]. *Post Marketing Surveillance* 1992;6:5-6.
93. Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. *N Engl J Med* 1998;339:1797-802.
94. Flewett TH, Houlton JG. Influenzal encephalopathy and postinfluenzal encephalitis. *Lancet* 1958;2:11-5.
95. Horner FA. Neurologic disorders after Asian influenza. *N Engl J Med* 1958;258:983-5.
96. Jacobs BC, Rothbarth PH, van der Meche FG, et al. The spectrum of antecedent infections in Guillain-Barre syndrome: a case-control study. *Neurology* 1998;51:1110-5.
97. Guarino M, Casmiro M, D'Alessandro R. *Campylobacter jejuni* infection and Guillain-Barré syndrome: a case-control study. *Neuroepidemiology* 1998;17:296-302.
98. Sheikh KA, Nachamkin I, Ho TW, et al. *Campylobacter jejuni* lipopolysaccharides in Guillain-Barre syndrome: molecular mimicry and host susceptibility. *Neurology* 1998;51:371-8.

99. Prevots DR, Sutter RW. Assessment of Guillain-Barré syndrome mortality and morbidity in the United States: implications for acute flaccid paralysis surveillance. *J Infect Dis* 1997;175 (Suppl 1):S151–S155.
100. Barohn RJ, Saperstein DS. Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy [Review]. *Semin Neurol* 1998;18:49–61.
101. CDC. Prevention of pneumococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 1997;46(No. RR-8):1–24.
102. Grilli G, Fuiano L, Biasio LR, Pregliasco F, et al. Simultaneous influenza and pneumococcal vaccination in elderly individuals. *Eur J Epidemiol* 1997;13:287–91.
103. Fletcher TJ, Tunnicliffe WS, Hammond K, Roberts K, Ayres JG. Simultaneous immunisation with influenza vaccine and pneumococcal polysaccharide vaccine in patients with chronic respiratory disease. *BMJ* 1997;314:1663–5.
104. Kendal AP, Maassab HF, Alexandrova GI, Ghendon YZ. Development of cold-adapted recombinant live, attenuated influenza A vaccines in the USA and USSR. *Antiviral Res* 1981;1:339–65.
105. Maassab HF, DeBorde DC. Development and characterization of cold-adapted viruses for use as live virus vaccines. *Vaccine* 1985;3:355–69.
106. Murphy BR. Use of live attenuated cold-adapted influenza A reassortant virus vaccines in infants, children, young adults, and elderly adults. *Infect Dis Clin Pract* 1993;2:174–81.
107. Potter CW. Attenuated influenza virus vaccines. *Med Virol* 1994;4:279–92.
108. Clements ML, Stephens I. New and improved vaccines against influenza. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, eds. *New Generation Vaccines*, 2nd edition. New York, NY: Marcel Dekker, 1997:545–70.
109. Edwards KM, Dupont WD, Westrich MK, Plummer WD Jr, Palmer PS, Wright PF. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. *J Infect Dis* 1994;169:68–76.
110. Belshe R, Iacuzio D, Mendelman P, Wolff M. Efficacy of trivalent live attenuated intranasal influenza vaccine in children. In: *Programs and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy*. Washington, DC: American Society of Microbiology, 1998.
111. Mullaoly JP, Barker WH. Impact of type A influenza on children: a retrospective study. *Am J Public Health* 1982;72:1008–16.
112. Glezen WP, Decker M, Joseph SW, Mercready RG Jr. Acute respiratory disease associated with influenza epidemics in Houston, 1981–1983. *J Infect Dis* 1987;155:1119–25.
113. Cooney MK, Fox JP, Hall CE. The Seattle Virus Watch. VI. Observations of infections with and illness due to parainfluenza, mumps and respiratory syncytial viruses and *Mycoplasma pneumoniae*. *Am J Epidemiol* 1975;101:532–51.
114. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. *Am J Dis Child* 1986;140:543–6.
115. Glezen WP. Morbidity associated with the major respiratory viruses. *Pediatr Ann* 1990;19: 535–42.
116. Couch RB, Kasel JA, Glezen WP, et al. Influenza: its control in persons and populations. *J Infect Dis* 1986;153:431–40.
117. Keyser LA, Karl M, Nafziger AN, Bertino JS Jr. Comparison of adverse events (AEs) of amantadine (AM) and rimantadine (RM) used as sequential prophylaxis of influenza A (FLU) in elderly nursing home residents. In: *Programs and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy*. Washington, DC: American Society of Microbiology, 1998.
118. Dolin R, Reichman RC, Madore HP, Maynard R, Linton PN, Webber-Jones J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. *N Engl J Med* 1982;307:580–4.
119. Gross PA, Russo C, Dran S, Cataruozolo P, Munk G, Lancey SC. Time to earliest peak serum antibody response to influenza vaccine in the elderly. *Clin Diagn Lab Immunol* 1997;4:491–2.
120. Brokstad KA, Cox RJ, Olofsson J, Jonsson R, Haaheim LR. Parental influenza vaccination induces a rapid systemic and local immune response. *J Infect Dis* 1995;171:198–203.
121. Tominack RL, Hayden FG. Rimantadine hydrochloride and amantadine hydrochloride use in influenza A virus infections. *Infect Dis Clin North Am* 1987;1:459–78.

122. Soung L-S, Ing TS, Daugirdas JT, et al. Amantadine hydrochloride pharmacokinetics in hemodialysis patients. *Ann Intern Med* 1980;93(Part 1):46-9.
123. Capparelli EV, Stevens RC, Chow MSS, Izard M, Wills RJ. Rimantadine pharmacokinetics in healthy subjects and patients with end-stage renal failure. *Clin Pharmacol Ther* 1988;43:536-41.
124. Schnack H, Wewalka F, Guttman G. Liver function during amantadine hydrochloride medication in compensated liver disease. *Internationale Zeitschrift fur Klinische Pharmakologie, Therapie, und Toxikologie* 1969;2:185-7.
125. Atkinson WL, Arden NH, Patriarca PA, Leslie N, Lui K-J, Gohd R. Amantadine prophylaxis during an institutional outbreak of type A (H1N1) influenza. *Arch Intern Med* 1986;146:1751-6.
126. Soo W. Adverse effects of rimantadine: summary from clinical trials. *J Respir Dis* 1989;10: S26-S31.
127. Bleidner WE, Harmon JB, Hewes WE, Lynes TE, Hermann EC. Absorption, distribution and excretion of amantadine hydrochloride. *J Pharmacol Exp Ther* 1965;150:484-90.
128. Douglas RG Jr. Drug therapy: prophylaxis and treatment of influenza. *N Engl J Med* 1990;322: 443-50.
129. Aoki FY, Sitar DS. Clinical pharmacokinetics of amantadine hydrochloride. *Clin Pharmacokinet* 1988;14:35-51.
130. Aoki FY, Sitar DS. Amantadine kinetics in healthy elderly men: implications for influenza prevention. *Clin Pharmacol Ther* 1985;37:137-44.
131. Guay DRP. Amantadine and rimantadine prophylaxis of influenza A in nursing homes: a tolerability perspective. *Drugs Aging* 1994;5:8-19.
132. Wintermeyer SM, Nahata MC. Rimantadine: a clinical perspective. *Ann Pharmacother* 1995; 29:299-310.
133. Wills RJ, Belshe R, Tomlinsin D, et al. Pharmacokinetics of rimantadine hydrochloride in patients with chronic liver disease. *Clin Pharmacol Ther* 1987;42:449-54.
134. Forest Pharmaceuticals. Flumadine<sup>®</sup> tablets. Flumadine<sup>®</sup> syrup (rimantadine hydrochloride) [Package insert]. St. Louis, MO: Forest Pharmaceuticals, 1993.
135. Wills RJ. Update on rimantadine's clinical pharmacokinetics. *J Respir Dis* 1989;10(suppl): S20-S25.
136. Belshe RB, Smith MH, Hall CB, Betts R, Hay AJ. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. *J Virol* 1988;62:1508-12.
137. Hall CB, Dolin R, Gala CL, et al. Children with influenza A infection: treatment with rimantadine. *Pediatrics* 1987;80:275-82.
138. Hayden FG, Sperber SJ, Belshe RB, Clover RD, Hay AJ, Pyke S. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. *Antimicrob Agents Chemother* 1991; 35:1741-7.
139. Houck P, Hemphill M, LaCroix S, Hirsh D, Cox N. Amantadine-resistant influenza A in nursing homes. Identification of a resistant virus prior to drug use. *Arch Intern Med* 1995;155:533-7.
140. Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. *N Engl J Med* 1989;321:1696-702.
141. Mast EE, Harmon MW, Gravenstein S, et al. Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2). *Am J Epidemiol* 1991;134:988-97.
142. Hayden FG, Hay AJ. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. *Curr Top Microbiol Immunol* 1992;176:119-30.
143. Degelau J, Somani SK, Cooper SL, Guay DRP, Crossley KB. Amantadine-resistant influenza A in a nursing facility. *Arch Intern Med* 1992;152:390-2.
144. Calfee DR, Hayden FG. New approaches to influenza chemotherapy: neuraminidase inhibitors [Review]. *Drugs* 1998;56:537-53.
145. Hayden FG, Treanor JJ, Betts RF, Lobo M, Esinhart JD, Hussey EK. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. *JAMA* 1996;275:295-9.
146. Hayden FG, Osterhaus ADME, Treanor JJ, et al., for the GG167 Influenza Study Group. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. *N Engl J Med* 1997;337:874-80.
147. Anonymous. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. *Lancet* 1998;352:1877-81.







The *Morbidity and Mortality Weekly Report (MMWR) Series* is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy on Friday of each week, send an e-mail message to [listserv@listserv.cdc.gov](mailto:listserv@listserv.cdc.gov). The body content should read *SUBscribe mmwr-toc*. Electronic copy also is available from CDC's World-Wide Web server at <http://www.cdc.gov/> or from CDC's file transfer protocol server at <ftp.cdc.gov>. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone (202) 512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the *MMWR* Series, including material to be considered for publication, to: Editor, *MMWR* Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone (888) 232-3228.

All material in the *MMWR* Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Director, Centers for Disease Control and Prevention Jeffrey P. Koplan, M.D., M.P.H.	Director, Epidemiology Program Office Stephen B. Thacker, M.D., M.Sc.	Writers-Editors, <i>MMWR</i> (weekly) Jill Crane
Deputy Director, Centers for Disease Control and Prevention Claire V. Broome, M.D.	Editor, <i>MMWR</i> Series John W. Ward, M.D.	David C. Johnson Teresa F. Rutledge Caran R. Wilbanks
	Managing Editor, <i>MMWR</i> (weekly) Karen L. Foster, M.A.	Desktop Publishing Morie M. Higgins Peter M. Jenkins

☆ U.S. Government Printing Office: 1999-733-228/87070 Region IV

**DEPARTMENT OF  
HEALTH AND HUMAN SERVICES**  
Centers for Disease Control  
and Prevention (CDC)  
Atlanta, Georgia 30333

**Official Business**  
Penalty for Private Use \$300  
Return Service Requested

**FIRST-CLASS MAIL  
POSTAGE & FEES PAID  
PHS/CDC  
Permit No. G-284**



The *Morbidity and Mortality Weekly Report (MMWR) Series* is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy on Friday of each week, send an e-mail message to [listserv@listserv.cdc.gov](mailto:listserv@listserv.cdc.gov). The body content should read *SUBscribe mmwr-toc*. Electronic copy also is available from CDC's World-Wide Web server at <http://www.cdc.gov/> or from CDC's file transfer protocol server at <ftp.cdc.gov>. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone (202) 512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the *MMWR* Series, including material to be considered for publication, to: Editor, *MMWR* Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone (888) 232-3228.

All material in the *MMWR* Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Director, Centers for Disease Control and Prevention Jeffrey P. Koplan, M.D., M.P.H.	Director, Epidemiology Program Office Stephen B. Thacker, M.D., M.Sc.	Writers-Editors, <i>MMWR</i> (weekly) Jill Crane
Deputy Director, Centers for Disease Control and Prevention Claire V. Broome, M.D.	Editor, <i>MMWR</i> Series John W. Ward, M.D.	David C. Johnson Teresa F. Rutledge Caran R. Wilbanks
	Managing Editor, <i>MMWR</i> (weekly) Karen L. Foster, M.A.	Desktop Publishing Morie M. Higgins Peter M. Jenkins

☆ U.S. Government Printing Office: 1999-733-228/87070 Region IV

UNITED STATES GOVERNMENT PRINTING OFFICE  
SUPERINTENDENT OF DOCUMENTS  
Washington, D.C. 20402

OFFICIAL BUSINESS  
Penalty for Private Use, \$300  
Return Service Requested

BULK RATE  
POSTAGE & FEES PAID  
GPO  
Permit No. G-26